Crescent Biopharma
- Market cap
- 499.39M
- P/E (TTM)i
- -96.03
- P/Bi
- 3.14
- EPSi
- -12.81
- Div yieldi
- 0.00%
- 52W posi
- 25%
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
- The number of reporting institutions increased by 3 in the most recent period (2026/Q3).
- Total institutional ownership fell 20.8 percentage points.
Institutional ownership
- Held by institutions
- 83.68% -20.75pp
- Institutions
- 104 +3
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
AlignedInstitutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Top holders as of 2025-04-15
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
25 filings tracked · 20 buys · 4 sells
| Name | Role | Stake |
|---|---|---|
| Edwin Rock | Senior VP & Chief Medical Officer | 0.02% |
| Brian Hahn | Senior Vice President | 0.00% |
| Harout Semerjian | Chief Executive Officer | 0.00% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2024-08-07 | Artal Group S.A. | -- | Open Market Disposition | -322,361 | $0.18–0.19 |
| 2024-08-05 | Artal Group S.A. | -- | Open Market Disposition | -220,255 | $0.18–0.19 |
| 2024-08-01 | Artal Group S.A. | -- | Open Market Disposition | -349,764 | $0.20–0.22 |
| 2024-07-29 | Artal Group S.A. | -- | Open Market Disposition | -1,379,119 | $0.22–0.24 |
| 2024-07-24 | Artal Group S.A. | -- | Initial Statement of Beneficial | 0 | -- |
| 2024-06-20 | Edwin Rock | Senior VP & Chief Medical Officer | Open Market Acquisition | +305,000 | $0.25–0.27 |
| 2024-06-17 | Brian Hahn | Senior Vice President | Open Market Acquisition | +17,500 | $0.25 |
| 2024-04-30 | Daniel Junius | Independent Director | Other Derivative Acquisition | +40,000 | $1.62 |
| 2024-04-30 | Mark Goldberg | -- | Other Derivative Acquisition | +40,000 | $1.62 |
| 2024-04-30 | Timothy Pearson | Independent Chairperson | Other Derivative Acquisition | +40,000 | $1.62 |
| 2024-04-30 | Scott Koenig | Independent Director | Other Derivative Acquisition | +40,000 | $1.62 |
| 2024-04-30 | Rachel King | Co-Founder | Other Derivative Acquisition | +40,000 | $1.62 |
| 2024-04-30 | Scott Jackson | Independent Director | Other Derivative Acquisition | +40,000 | $1.62 |
| 2024-04-30 | Patricia Susan Andrews | Independent Director | Other Derivative Acquisition | +40,000 | $1.62 |
| 2024-03-28 | Daniel Junius | Independent Director | Other Acquisition | +5,209 | $3.00 |
| 2024-03-28 | Mark Goldberg | -- | Other Acquisition | +4,584 | $3.00 |
| 2024-03-28 | Rachel King | Co-Founder | Other Acquisition | +3,334 | $3.00 |
| 2024-01-11 | Brian Hahn | Senior Vice President | Other Derivative Acquisition | +250,000 | $3.11 |
| 2024-01-11 | Harout Semerjian | Chief Executive Officer | Other Derivative Acquisition | +695,000 | $3.11 |
| 2024-01-11 | Edwin Rock | Senior VP & Chief Medical Officer | Other Derivative Acquisition | +250,000 | $3.11 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-08 09:54:40 · For reference only, not investment advice and not tailored to your situation.